Skip to main content Back to Top
Advertisement

9/30/2019

Lorazepam Tablets

Products Affected - Description

    • Ativan tablet, Bausch Health, 1 mg, bottle, 100 count, NDC 00187-0064-01
    • Ativan tablet, Bausch Health, 1 mg, bottle, 1000 count, NDC 00187-0064-10
    • Lorazepam tablet, Leading, 0.5 mg, bottle, 100 count, NDC 69315-0904-01
    • Lorazepam tablet, Leading, 0.5 mg, bottle, 500 count, NDC 69315-0904-05
    • Lorazepam tablet, Leading, 0.5 mg, bottle, 1000 count, NDC 69315-0904-10
    • Lorazepam tablet, Leading, 1 mg, bottle, 100 count, NDC 69315-0905-01
    • Lorazepam tablet, Leading, 1 mg, bottle, 500 count, NDC 69315-0905-05
    • Lorazepam tablet, Leading, 1 mg, bottle, 1000 count, NDC 69315-0905-10
    • Lorazepam tablet, Leading, 2 mg, bottle, 100 count, NDC 69315-0906-01
    • Lorazepam tablet, Leading, 2 mg, bottle, 500 count, NDC 69315-0906-05
    • Lorazepam tablet, Leading, 2 mg, bottle, 1000 count, NDC 69315-0906-10
    • Lorazepam tablet, Major, 0.5 mg, bottle, 100 count, NDC 00904-6007-60
    • Lorazepam tablet, Major, 0.5 mg, unit-dose blister pack, 100 count, NDC 00904-6007-61
    • Lorazepam tablet, Major, 1 mg, bottle, 100 count, NDC 00904-6008-60
    • Lorazepam tablet, Major, 1 mg, unit-dose blister pack, 100 count, NDC 00904-6008-61
    • Lorazepam tablet, Major, 2 mg, bottle, 100 count, NDC 00904-6009-60
    • Lorazepam tablet, Major, 2 mg, unit-dose blister pack, 100 count, NDC 00904-6009-61
    • Lorazepam tablet, Mylan Institutional, 0.5 mg, unit-dose blister pack, 100 count, NDC 51079-0417-20 - discontinued
    • Lorazepam tablet, Mylan Institutional, 1 mg, unit-dose blister pack, 100 count, NDC 51079-0386-20 - discontinued
    • Lorazepam tablet, Mylan Institutional, 2 mg, unit-dose blister pack, 100 count, NDC 51079-0387-20 - discontinued
    • Lorazepam tablet, Teva, 0.5 mg, bottle, 100 count, NDC 00591-0240-01
    • Lorazepam tablet, Teva, 0.5 mg, bottle, 500 count, NDC 00591-0240-05
    • Lorazepam tablet, Teva, 0.5 mg, bottle, 1000 count, NDC 00591-0240-10
    • Lorazepam tablet, Teva, 1 mg, bottle, 100 count, NDC 00591-0241-01
    • Lorazepam tablet, Teva, 1 mg, bottle, 1000 count, NDC 00591-0241-10
    • Lorazepam tablet, Teva, 2 mg, bottle, 100 count, NDC 00591-0242-01

Reason for the Shortage

    • Aurobindo refuses to provide availability information.
    • Leading has all lorazepam tablet presentations on intermittent back order due to increased demand.
    • Major did not provide a reason for the shortage.
    • Mylan has discontinued all bottled presentations.
    • Mylan Institutional discontinued all unit-dose blister pack presentations.
    • Sandoz discontinued all lorazepam presentations.
    • Teva did not provide a reason for the shortage.

Available Products

    • Ativan tablet, Bausch Health, 0.5 mg, bottle, 100 count, NDC 00187-0063-01
    • Ativan tablet, Bausch Health, 2 mg, bottle, 100 count, NDC 00187-0065-01
    • Lorazepam tablet, Teva, 1 mg, bottle, 500 count, NDC 00591-0241-05
    • Lorazepam tablet, Teva, 2 mg, bottle, 500 count, NDC 00591-0242-05
    • Lorazepam tablet, Teva, 2 mg, bottle, 1000 count, NDC 00591-0242-10

Estimated Resupply Dates

    • Bausch Health has Ativan 1 mg tablets on back order and the company cannot estimate a release date.
    • Major has all lorazepam tablet presentations on back order and the company cannot estimate a release date.
    • Leading has all lorazepam tablet presentations on intermittent back order and they are releasing product as it becomes available.
    • Teva has lorazepam 0.5 mg tablets in 100 count, 500 count, and 1,000 count bottles, 1 mg tablets in 1,000 count bottles, and 2 mg tablets in 100 count bottles on back order and the company estimates a release date of early- to mid-October 2019. The 1 mg tablets in 100 count are on back order and the company estimates release dates of mid-October 2019.

Updated

Updated September 30, 2019 by Stephen Andrews, PharmD, BCPS, Drug Information Specialist. Created October 4, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins